**M3 Literature Review**

**Period: 08/08/2025 – 08/09/2025**

[Scientific Highlights: 1](#_Toc143520007)

[Clostridioides difficile/ Clostridium difficile 3](#_Toc143520008)

[Fidaxomicin & Clostridium difficile 4](#_Toc143520009)

[Clostridioides difficile vaccine 4](#_Toc143520010)

[Vancomycin & CDI 4](#_Toc143520011)

[CDI 4](#_Toc143520012)

[FMT/ Fecal Microbiota Transplant 5](#_Toc143520013)

[Competitors 5](#_Toc143520014)

[CDAD 6](#_Toc143520015)

[CMC 6](#_Toc143520016)

[Guidelines 6](#_Toc143520017)

[Non-toxigenic C. difficile 6](#_Toc143520018)

[MGB 6](#_Toc143520019)

[Other news of possible interest 7](#_Toc143520020)

Scientific Highlights:

1. Clostridioides difficile in Children.
2. Safety and Efficacy of Fecal Microbiota, Live-jslm to Prevent Recurrent Clostridioides difficile Infection in Participants With Irritable Bowel Syndrome.
3. The interplay of dyadic adjustment, sleep quality, and CPAP adherence in OSAS: A cross-sectional study on illness perceptions and depressive symptoms.
4. Management of diarrhea in solid organ transplantation.
5. The role of Frailty Index Laboratory in predicting clinical outcomes in patients with Clostridioides difficile infections: a 2020-24 single-centre retrospective study.
6. Microbiome Therapeutics for Clostridioides difficile Infection.
7. Making Sense of Differing Guidelines for Clostridioides difficile Infection.
8. Impact of Clostridium difficile Infection on Chemotherapy in Patients With Primary Ovarian Cancer.
9. Emerging Clostridioides difficile strains belonging to PCR ribotype955 in Serbia are distinct from metronidazole resistant RT955 outbreak isolates from the UK.
10. Epitope conservation of AZD5148, a broadly neutralizing anti-Toxin B monoclonal antibody, among diverse and global contemporary Clostridioides difficile isolates.
11. Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease and Clostridioides difficile: An Updated Literature Review.
12. Case Report of Nephrogenic Diabetes Insipidus with a Novel Mutation in the AQP2 Gene.
13. Clostridioides difficile toxin A and toxin B inhibit toxin-specific adaptive immune responses through glucosyltransferase-dependent activity.
14. Long read metagenomics-based precise tracking of bacterial strains and genomic changes after fecal microbiota transplantation.
15. Recurrent Clostridioides difficile Infection in a Patient With Chronic Colitis: A Successful Response to Fecal Microbiota Transplantation.
16. Advances in the Medical Treatment of Clostridioides difficile Infection.
17. Alpha-Synuclein Lesions in the Peripheral Nervous System of the Larynx in Parkinson's Disease.
18. In Vitro Characterization of PHICD111\_20024\_EAD as an Engineered Endolysin against Clostridioides difficile.
19. Regional epidemiologic data call for enhanced attention to Clostridioides difficile infections in Italy: Results from a population-based study.
20. Risk factors for further recurrences of Clostridioides difficile infection at the first and second recurrence: a retrospective cohort.
21. What's New and What's Next in Fecal Microbiota Transplantation?
22. Clostridioides difficile in Peripartum Women: Review of Outcomes and Treatment.
23. Standardized freeze-dried FMT: is the ideal protectant out there?
24. Advancing Access to Intestinal Microbiota Transplant: Bridging the Gap Between National Practices and the European Strategy.
25. Bezlotoxumab as Treatment for Recurrent/Chronic Clostridioides difficile Infection in Pediatric Stem Cell Transplant Recipients: A Multi-Institutional Experience.
26. Mitomycin Intravesical Solution: First Approval.
27. Epidemiology and Course of Clostridioides difficile Infections in Germany: Retrospective Analysis of German Health Claims Data.
28. Predictive Modeling for Clostridioides difficile Infection: Current State of the Science, Clinical Applications, and Future Directions.
29. Assessment of chemical methods in the extraction of spore surface layers in Clostridioides difficile spores.
30. Fecal microbiota transplantation as a therapeutic modality for recurrent Clostridioides difficile infection: reviewing efficacy, safety, mechanisms of action, and outcomes.
31. Diagnostic Approaches for Clostridioides difficile Infection.

Clostridioides difficile/ Clostridium difficile

1. Antibiotic Use and the Risk of Hospital-Onset Clostridioides Difficile Infection.
2. Clinical burden of Clostridioides difficile infection in infective endocarditis: a single-center experience.
3. Faecal pharmacokinetics, microbiome, and bile acid changes in healthy subjects given intravenous followed by oral omadacycline; a Phase 1 clinical trial.
4. Management of Severe Clostridioides difficile Infection.
5. Synthetic niclosamide-loaded controlled-release nanospheres with high solubility and stability exerting multiple effects against Clostridioides difficile.
6. The Impact of Obesity on Clostridioides difficile Infection Outcomes: A Retrospective Cohort Study.
7. Akkermansia muciniphila: A key player in gut microbiota-based disease modulation.
8. Mycobiota Dynamics in Inflammatory Bowel Disease: Fungal Biomarkers and Clostridioides difficile Co-infection.
9. [Therapy of Clostridioides difficile infection].
10. Clostridioides difficile Infections: Epidemiological and Laboratory Data from the Internal Medicine Departments of a Tertiary Care Hospital in Athens, Greece, During the Past Decade.
11. Madecassoside alleviates Clostridioides difficile infection by targeting ASC to inhibit inflammasome activation.
12. Detecting and mitigating doppelgänger bias in microbiome data: impacts on machine learning and disease classification.
13. Detection and Risk Factor Analysis of Clostridioides Difficile Infection in Patients with Malignant Tumours.

Fidaxomicin & Clostridium difficile

1. Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service.

Clostridioides difficile vaccine

1. Immune Aspects of Clostridioides difficile Infection and Vaccine Development.
2. Multi-epitope vaccine design against Clostridioides difficile using the ABC-type transport system protein.
3. Microbial bellwether: Community-scale metabolic modeling to predict infection.
4. Mouse monoclonal antibodies against Clostridioides difficile toxins TcdA and TcdB target diverse epitopes for neutralization.

Vancomycin & CDI

1. An anaerobic in vitro flow model for studying interactions at the gastrointestinal host-microbe interface.
2. Screening and Targeted Prophylaxis for Clostridioides difficile Infection: STOP-CDI.
3. Clostridioides difficile Infection in the United States of America-A Comparative Event Risk Analysis of Patients Treated with Fidaxomicin vs. Vancomycin Across 67 Large Healthcare Providers.
4. Dominance of toxigenic Clostridioides difficile strains and the appearance of the emerging PCR ribotype 955 in hospitals in Silesia, Poland.
5. Healthcare-associated infections and antimicrobial resistance in Canadian acute care hospitals, 2019-2023.
6. Impact of enhanced infection control and antimicrobial stewardship on infections by Clostridioides difficile, vancomycin-resistant enterococci, and third-generation cephalosporin-resistant Enterobacterales: A stepped-wedge cluster intervention study.

CDI

FMT/ Fecal Microbiota Transplant

1. Operational considerations for the running of an NHS faecal microbiota transplant (FMT) service.

Competitors

1. The Dream and MEC NuRD Complexes reinforce SPR-5/MET-2 maternal reprogramming to maintain the germline-soma distinction.
2. SUSCEPTIBILITY OF MULTI-DRUG RESISTANT ESCHERICHIA COLI AND KLEBSIELLA PNEUMONIAE TO ORAL ANTIBIOTICS IN AUSTRALIA.
3. Effective Aerosol Inoculation of Dose-Escalated Seasonal Influenza H3N2 Virus in Controlled Human Infection Model.
4. Phenotypic and genotypic profiles of clinical isolates of various Nocardia species to carbapenems and fluoroquinolones.
5. The neuroendocrine regulation of hepatic cytochrome P450 by N-methyl-D-aspartate receptors in the paraventricular and arcuate nuclei of the hypothalamus.
6. The oral penems and carbapenems.
7. An evaluation of antibiotic options for the treatment of biothreat pathogens.

CDAD

1. Safety and tolerability of onasemnogene abeparvovec for patients with spinal muscular atrophy weighing ≤17 kg and ≤24 months old from OFELIA, a phase 4, open-label, multicenter, non-randomised, interventional study.
2. Anaerobic gut bacteria and their potential role in the initiation, exacerbation, and development of human colorectal cancer: a narrative review.
3. Haemophagocytic Lymphohistiocytosis: An Uncommon Presentation in Systemic Lupus Erythematosus and Acute Leukaemia.
4. Irritable bowel syndrome after Clostridioides difficile infection.
5. Gastrointestinal Infection Before Immune Checkpoint Inhibition Hinders Treatment Efficacy and Increases the Risk of Colitis.
6. Safety profile of belatacept in a real-life setting: disproportionality analysis of the WHO pharmacovigilance database.
7. Chronic Kidney Disease as a Predictor of Mortality in Hospitalized Inflammatory Bowel Disease Patients With Clostridioides difficile Infection.
8. Increase of Clostridioides difficile PCR ribotype 002 infection with decreased disease severity in hospitalized patients in the Netherlands.
9. Impact of gastrointestinal complications on readmission and resource use after kidney transplantation.
10. Antibiotic treatment for 7 days versus 14 days in patients with uncomplicated bloodstream infections: a Systematic review and meta-analysis of randomized controlled trials and trial sequential analysis.
11. Preschoolers in severely food insecure Guatemalan Mayan households consume a monotonous grain-based diet.
12. Veillonella intestinal colonization promotes C. difficile infection in Crohn's disease.
13. Genomic Epidemiology of Clostridioidesdifficile.
14. In vivo efficacy of fidaxomicin against rpoB mutant Clostridioides difficile infection.
15. Temporally segregated subpopulations of CDT and TcdA producer cells of Clostridioides difficile.
16. Intracranial Injury Following Nasogastric Tube Placement After Skull Base Surgery: A Case Report and Systematic Review.
17. Phase variation of Clostridioides difficile colony morphology occurs via modulation of cell division.
18. Radial ESWT combined with a specific rehabilitation program (rESWT+RP) is more effective than sham rESWT+RP for acute hamstring muscle complex injury type 3b: a randomized, controlled trial.

CMC

1. Pushing the resolution limit of coherent diffractive imaging.

Guidelines

1. The Role of Microbial-Derived p-Cresol in Autism Spectrum Disorder: A Systematic Review of the Gut-Brain Axis.
2. From guesswork to guidelines: advancing diagnostic stewardship in immunocompromised hosts.
3. Unusual Presentation of Necrotizing Enterocolitis Presenting in a Term Infant.
4. Duration of Therapy With Amoxicillin/Clavulanate for Postoperative Antimicrobial Prophylaxis of Fractures of the Facial Skeleton: A Systematic Review and Meta-Analysis.
5. Management of Clostridioides difficile infection in patients with haematological malignancies and after cellular therapy: guidelines from 10th European Conference on Infections in Leukaemia (ECIL-10).
6. Variations in Stress Ulcer Prophylaxis Practices Among Intensive Care Units in Makkah City Hospitals, Kingdom of Saudi Arabia.
7. A Systematic Review of the Adverse Effects of Long-Term Proton Pump Inhibitor Use on the Gastrointestinal System in the Adult Population.
8. Investigating the relationship between Helicobacter pylori and intestinal Clostridioides difficile infection: evidence from a cross-sectional study.
9. Advances in diagnosis of diseases causing diarrhea in newborn calves.
10. Trametinib-Induced Hyponatremia in a Patient With Craniopharyngioma and Diabetes Insipidus.
11. Short-course intravenous beta-lactams for uncomplicated cystitis in hospitalized patients.

Non-toxigenic C. difficile

1. Membrane vesicles from selected Clostridioides difficile strains induce epithelial-mesenchymal transition in colonic epithelial cells: insights from in vitro and in vivo studies.

MGB

Other news of possible interest